Article
Microbiology
Taylor Morrisette, Kyle C. Stamper, Katherine L. Lev, Razieh Kebriaei, Dana J. Holger, Jacinda C. Abdul-Mutakabbir, Ashlan J. Kunz Coyne, Michael J. Rybak
Summary: Biofilm-associated infections are a major cause of illness. Omadacycline (OMC) is a new drug with high activity against certain bacteria, but its effectiveness in treating biofilm-associated infections is uncertain.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Cristina El Haj, Mads Lichtenberg, Karen Leth Nielsen, Thomas Bjarnsholt, Peter ostrup Jensen
Summary: This study evaluated the role of ROS in the bactericidal activity of daptomycin against Staphylococcus aureus biofilms. The presence of catalase was found to protect the biofilm by reducing ROS production and increasing bacterial survival. Induction of cytotoxic ROS formation by daptomycin was verified, and only the highest concentration of daptomycin reduced bacterial survival and increased ROS formation in the resistant biofilm.
Review
Infectious Diseases
Chienhsiu Huang, Ihung Chen, Lichen Lin
Summary: Combination therapy with daptomycin plus ceftaroline may reduce mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. The combination therapy group had similar in-hospital mortality, duration of bacteremia, and adverse event rate compared to the monotherapy group, but had lower bacteremia recurrence.
Article
Infectious Diseases
Jasmina Al Janabi, Staffan Tevell, Raphael Niklaus Sieber, Marc Stegger, Bo Soderquist
Summary: This study investigated the susceptibility of Staphylococcus epidermidis strains from prosthetic joint infections to dalbavancin and the genomic variation in strains with reduced susceptibility. The results suggest that exposure to dalbavancin may lead to reduced susceptibility through selection of pre-existing subpopulations, epigenetic changes, or spontaneous mutations during antibiotic exposure. Therefore, source control and adequate antibiotic concentrations are important to prevent emerging reduced susceptibility during dalbavancin treatment.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Chemistry, Medicinal
Jiepeng Tong, Yiheng Jiang, Hao Xu, Xuehang Jin, Li Zhang, Shuaibing Ying, Wei Yu, Yunqing Qiu
Summary: The emergence of vancomycin-resistant Enterococci (VRE) is limiting treatment options for infections. This study investigated the resistance mechanism and evaluated the effects of different antibiotics alone or in combination against VRE isolates. The results suggest that FM combined with DAP could be a potential therapeutic option for VRE infections.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Microbiology
Melissa J. Karau, Suzannah M. Schmidt-Malan, Scott A. Cunningham, Jayawant N. Mandrekar, Bobbi S. Pritt, Tiffany R. Keepers, Alisa W. Serio, Surya Chitra, Robin Patel
Summary: Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of MRSA osteomyelitis. The results showed that rifampin combination therapy was effective in reducing MRSA recovery without developing resistance. The combination of omadacycline and rifampin yielded negative MRSA detection, suggesting its potential as a treatment for osteomyelitis.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Microbiology
Tiep K. Nguyen, Frederic Peyrusson, Wafi Siala, Nhung H. Pham, Hoang A. Nguyen, Paul M. Tulkens, Francoise Van Bambeke
Summary: Staphylococcus aureus biofilms are resistant to antibiotics due to factors such as drug access blockage and presence of dormant bacteria. Clinical isolates produce more biofilm biomass than the reference strain, especially those with high persister fractions. Moxifloxacin is less effective against biofilms from clinical isolates, attributed to lower drug concentration and presence of moxifloxacin-tolerant subpopulations.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Infectious Diseases
Louis D. Saravolatz, Joan Pawlak
Summary: Fosfomycin exhibited excellent activity against MRSA, including isolates with reduced susceptibility or resistance to other anti-MRSA drugs. Synergy was observed when fosfomycin was combined with linezolid or daptomycin. These combinations may have potential clinical utility in treating serious infections caused by MRSA.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Carlos F. Amabile-Cuevas
Summary: Biofilm formation by macrolide-resistant Staphylococcus aureus isolates can be induced by macrolides, especially in the early stages, suggesting that the empirical use of macrolides against infections caused by resistant S. aureus strains could lead to clinical failure or even enhance biofilm formation, making further treatment difficult.
Review
Pharmacology & Pharmacy
Masaru Samura, Yuki Kitahiro, Sho Tashiro, Hiromu Moriyama, Yuna Hamamura, Isamu Takahata, Rina Kawabe, Yuki Enoki, Kazuaki Taguchi, Yoshio Takesue, Kazuaki Matsumoto
Summary: This systematic review and meta-analysis compares the efficacy of daptomycin and vancomycin in adult patients with bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with a vancomycin minimum inhibitory concentration (MIC) > 1 mu g/mL. The results show that daptomycin treatment is associated with lower mortality and higher treatment success compared to vancomycin, regardless of the vancomycin MIC test method used. Daptomycin should be considered as a treatment option for MRSA bacteremia with a vancomycin MIC > 1 mu g/mL, especially in patients with intermediate- and high-risk bacteremia sources.
Review
Infectious Diseases
Alberto Enrico Maraolo, Agnese Giaccone, Ivan Gentile, Annalisa Saracino, Davide Fiore Bavaro
Summary: In the treatment of MRSA infections, daptomycin appears to be associated with a lower risk of clinical failure and treatment-limiting adverse events compared to vancomycin. Further studies are needed to better understand the differences between the two drugs.
Article
Infectious Diseases
Maria Simitsopoulou, Paschalis Kadiltzoglou, Charalampos Antachopoulos, Emmanuel Roilides
Summary: This study found that Daptomycin (DAP) has a synergistic effect on MRSA biofilms, enhancing the damage caused by human polymor-phonuclear neutrophils (PMNs). Additionally, DAP can modulate the immune response of human monocytes (MNCs) to MRSA biofilms through upregulation of Toll-like receptor 2 (TLR2) and increased NLRP3 inflammasome production, potentially controlling biofilm-associated pathogenicity.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Immunology
Pernille Ommen, Line Hansen, Bente K. Hansen, Hieu Vu-Quang, Jorgen Kjems, Rikke L. Meyer
Summary: In this study, an aptamer-targeted liposomal drug delivery system was developed to eradicate Staphylococcus aureus biofilm infections in vitro.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Immunology
Marin L. Schweizer, Kelly Richardson, Mary S. Vaughan Sarrazin, Michihiko Goto, Daniel J. Livorsi, Rajeshwari Nair, Bruce Alexander, Brice F. Beck, Michael P. Jones, Mireia Puig-Asensio, Daniel Suh, Madeline Ohl, Eli N. Perencevich
Summary: Among patients with methicillin-resistant Staphylococcus aureus bloodstream infections, switching to daptomycin is associated with lower 30-day mortality, especially when done within 3 days of initial vancomycin receipt. However, switching to daptomycin at any time during the first hospitalization did not significantly affect 30-day mortality.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Virology
Hyonoo Joo, Sijia M. Wu, Isha Soni, Caroline Wang-Crocker, Tyson Matern, James Peter Beck, Catherine Loc-Carrillo
Summary: Staphylococcus aureus is the main cause of implant-related infections in the form of biofilms. The heavy use of broad-spectrum antibiotics against these pathogens contributes to the problem of antibiotic-resistant infections. Bacteriophages have the potential to be an alternative therapy.